Our Passion for Innovation

We are always researching and investigating innovative ways to help people living with psychiatric, neurological, oncology, urological and infectious diseases. Our ongoing pursuit of knowledge drives us forward and inspires our innovation. At Sumitomo Pharma Canada, we are dedicated to expanding our portfolio of products that matter most to the people we serve.

Focus Areas


Stock photo of an Asian man in his mid-30’s at work in a coffee store.

We are committed to the research and discovery of novel pathways and therapies to address some of the world’s most serious psychiatric conditions. Our goal is to develop therapies that transform the lives of people living with these conditions.


Bipolar Disorder

Bipolar disorder affects approximately 322,000 individuals in Canada and an estimated 29 million people worldwide. A person is usually diagnosed with bipolar disorder after experiencing at least one manic episode, with symptoms that are not better explained by another mental health condition, such as schizophrenia. Bipolar disorder is characterized by debilitating mood swings, interspersed with periods of stable mood and behavior. When individuals with bipolar disorder are experiencing symptoms, most tend to be depressed rather than manic.

Illustration of a world globe.
29 M
Estimated number of people affected by bipolar depression worldwide
Illustration of the map of the Canada.
322 K
Estimated number of Canadian adults who experience symptoms of bipolar depression



Schizophrenia is a chronic, serious, and often severely disabling brain disorder that affects more than 20 million people worldwide and approximately 308,000 people in Canada. It is characterized by positive symptoms, such as hallucinations, delusions, and disorganized thinking, as well as negative symptoms, such as lack of emotion, social withdrawal, lack of spontaneity, and cognitive impairment that includes problems with memory, attention, and the ability to plan, organize, and make decisions.

Illustration of a world globe.
20 M
Estimated number of people affected by schizophrenia worldwide
Illustration of the map of the Canada.
308 K
Estimated number of Canadian adults who are diagnosed with schizophrenia


Stock photo of a Caucasian teenage male outdoors on a hike taking a self-portrait.

Our commitment to neurology and the people living with epilepsy is unwavering. Our ingenuity and innovative spirit are what helps us develop novel treatments that address the daily challenges people encounter living with serious neurological conditions.



Epilepsy is one of the most common neurological diseases globally, affecting approximately 50 million people worldwide. The condition is characterized by unpredictable seizures, which are caused by disturbances in the electrical activity in the brain. Someone is said to have epilepsy if they experience two or more unprovoked seizures separated by at least 24 hours or after one seizure with a high risk for more. It is estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated.

Illustration of a world globe.
50 M
Estimated number of people affected by epilepsy worldwide
Illustration of the map of the Canada.
300 K
Estimated number of Canadian adults who experience symptoms of epilepsy

Additional Resources


Our preclinical and clinical programs span numerous modalities and indications where patient needs remain high or unmet.


Stay up-to-date with the latest news from SMPA.